Feed KMDA
KM

Kamada Ltd.

KMDA · NASDAQ

$8.67 +3.09% (+$0.26)
1M +9.89%
Market Cap $500.2M
P/E Ratio 22.48x
Div. Yield 4.84%
ROE 8.37%

Bulios Fair Price

$12.16

40.3% upside

Current Price

$8.67

Undervalued Fair Value Overvalued

According to Bulios Fair Price, KMDA is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
70 /100
Cheap
P/FCF 18.89x
P/E 22.48x
P/B 1.86x
Growth
51 /100
Stable
Book val. growth 15.20%
Rev. growth 11.74%
FCF growth 11.94%
Profitability
74 /100
Strong
Op. margin 14.51%
Gross margin 40.82%
FCF margin 13.80%
Quality
41 /100
Average
ROA 5.81%
ROIC 6.90%
Asset turnover 0.50x
Debt
100 /100
Low
Int. coverage 25.72x
Debt/Equity 0.04x
Net debt/EBITDA -0.42x
Stability
38 /100
Moderate
EPS volatility 192.05%
Beta 0.14x
Profitable years 3

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about KMDA
Online

About the company

Kamada Ltd. (KMDA) is a biopharmaceutical company engaged in research, development, and manufacturing of therapeutic products. The company specializes in the development and production of protein therapeutics and immunoglobulins for various therapeutic applications. Kamada has developed a range of biological therapeutics and products aimed at treating rare and genetic diseases, including immune deficiencies and hematological disorders. With its innovative products and meticulous research, the company maintains a significant position in the biopharmaceutical sector. Kamada Ltd. (KMDA) also has extensive collaborations with international pharmaceutical companies for the distribution of its therapeutics and the development of new treatment possibilities. Kamada Ltd. (KMDA) shares may be an attractive investment opportunity for investors interested in the biopharmaceutical sector and seeking an investment in a company with an innovative portfolio of therapeutics and potential for further growth in treatment technologies.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Amir London

Employees

462

Headquarters

Rehovot

Upcoming events

09 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.